Form 4: Zevra Therapeutics Director Granted Stock Options

Tamara A. Favorito, a Director at Zevra Therapeutics, Inc., has been granted 30,000 stock options as compensation for her board service.

Summary

• Tamara A. Favorito, a Director of Zevra Therapeutics, Inc., received a grant of 30,000 stock options on June 4, 2026.
• These options have an exercise price of $11.17 per share, which was the closing price of Zevra's common stock on the grant date.
• The options are part of the company's compensation policy for non-employee directors.
• Vesting of the options occurs on the earlier of the first anniversary of the grant date, one day before the first annual stockholders meeting after the grant, or immediately prior to a change in control, provided Ms. Favorito remains in service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it pertains to standard director compensation and does not provide new financial or operational information about the company's performance.

Positives

• Director compensation is being provided through equity, aligning director interests with shareholders.
• The grant is made under an established compensation policy for non-employee directors.
• The exercise price is set at the current market price, indicating no immediate discount.
• Vesting provisions encourage continued service and alignment with company performance and control events.

Negatives

• The filing does not provide details on the company's financial performance or operational updates, focusing solely on director compensation.
• The value of the stock options is contingent on future stock price appreciation.

Risks

• The value of the granted stock options is subject to market volatility and the company's future stock performance.
• If the company's stock price does not increase above the exercise price of $11.17, the options may not hold significant value.
• Potential for dilution to existing shareholders if a large number of options are exercised.

Future Outlook

The future outlook for the stock options is dependent on the company's stock performance and the continued service of the director. The options are exercisable up to June 3, 2036, provided vesting conditions are met.

Industry Context

StockSavvy.ai notes that granting stock options to directors is a common practice in the biotechnology and pharmaceutical sectors to attract and retain experienced leadership and align their incentives with shareholder value creation. This type of compensation is standard for board members in publicly traded companies.

Comparison to Industry Standards

• The grant of 30,000 stock options to a director at an exercise price equal to the closing market price on the grant date is consistent with industry standards for non-employee director compensation in publicly traded companies, particularly within the biotech sector.
• Vesting schedules tied to continued service and corporate events like change of control are also typical, ensuring long-term commitment and alignment with strategic outcomes.

Corporate Governance

Related Party Transactions

• The grant of stock options to Director Tamara A. Favorito is a related party transaction, as she is a member of the board of directors.

Stakeholder Impact

• Shareholders: The grant of options represents potential future dilution, but also aligns director incentives with stock performance.
• Employees: This filing does not directly impact employees, but reflects the company's compensation structure for its board.
• Management: The filing is a routine disclosure related to executive and director compensation.

Next Steps

• Tamara A. Favorito is expected to continue her service as a Director of Zevra Therapeutics, Inc.
• The stock options will vest according to the schedule outlined in the filing.
• The company may continue to grant equity compensation to its directors and officers as per its compensation policies.

Key Dates

Keywords

Form 4, SEC Filing, Zevra Therapeutics, ZVRA, Director Compensation, Stock Options, Equity Grant, Beneficial Ownership, Insider Trading, Securities Exchange Act